A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

NCT04835805 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

65

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Belvarafenib
DRUG: Cobimetinib
DRUG: Nivolumab

Sponsor

Genentech, Inc.